4.10
前日終値:
$4.55
開ける:
$4.53
24時間の取引高:
104.98K
Relative Volume:
0.47
時価総額:
$144.84M
収益:
-
当期純損益:
-
株価収益率:
-2.0724
EPS:
-1.9784
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.74%
1か月 パフォーマンス:
+58.91%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
Anteris Technologies Global Corp Stock (AVR) Company Profile
名前
Anteris Technologies Global Corp
セクター
電話
651-493-0606
住所
860 BLUE GENTIAN ROAD, EAGAN
AVR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AVR
Anteris Technologies Global Corp
|
4.10 | 144.84M | 0 | 0 | 0 | -1.9784 |
![]()
ISRG
Intuitive Surgical Inc
|
565.94 | 192.17B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
171.02 | 47.90B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
87.24 | 47.53B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
RMD
Resmed Inc
|
246.99 | 35.88B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
COO
The Cooper Companies, Inc.
|
80.47 | 16.25B | 3.93B | 415.40M | 384.70M | 2.06 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-08 | 開始されました | Lake Street | Buy |
2025-01-07 | 開始されました | Barclays | Overweight |
2025-01-07 | 開始されました | Cantor Fitzgerald | Overweight |
2025-01-07 | 開始されました | TD Cowen | Buy |
Anteris Technologies Global Corp (AVR) 最新ニュース
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global (NASDAQ:AVR) Stock Price Down 6.2% – What’s Next? - Defense World
Anteris Technologies: Advancing Toward FDA Approval with Positive Buy Rating - TipRanks
Anteris Technologies reports annual financial results By Investing.com - Investing.com South Africa
Anteris Technologies reports annual financial results - Investing.com India
Anteris Technologies 2024 financials strong following Nasdaq debut, with plans for heart valve pivotal trial this year - Proactive financial news
Anteris Technologies: A Trailblazing Year of Innovation and Expansion - Kondor EXP
The morning catch up: ASX to reverse losses despite war of words over tariffs - Proactive financial news
Anteris Technologies Global Corp (AVR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):